Tag: price
-
U.S. lawmakers press Mylan on EpiPen price increases
Two senior lawmakers on the U.S. Senate’s Judiciary Committee on Monday pushed for information regarding sharp price increases for EpiPens, drug-filled injectable devices used by people to counter potentially deadly allergic reactions. Senator Chuck Grassley, chairman of the Senate Judiciary Committee, wrote Mylan Chief Executive Heather Bresch on Monday to ask how Mylan determined the…
-
U.S. lawmakers press Mylan on EpiPen price increases
Two senior lawmakers on the U.S. Senate’s Judiciary Committee on Monday pushed for information regarding sharp price increases for EpiPens, drug-filled injectable devices used by people to counter potentially deadly allergic reactions. Senator Chuck Grassley, chairman of the Senate Judiciary Committee, wrote Mylan Chief Executive Heather Bresch on Monday to ask how Mylan determined the…
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.4 percent at $34.84. The offer is a 55-percent premium to Sanofi SA's initial bid to buy Medivation for $52.50 per share in April, which pushed…
-
Exclusive: Makers took big price increases on widely used U.S. drugs
By Caroline Humer NEW YORK (Reuters) – Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found. Together, the price increases on drugs for arthritis, high cholesterol, asthma and other common…
-
Shkreli plans to remain silent at congressional hearing: letter
Former drug executive Martin Shkreli plans to assert his right against self-incrimination and remain silent if he is forced to appear at a congressional hearing in Washington next week about drug prices, according to a letter seen by Reuters. Shkreli's lawyer informed the U.S. House Committee on Oversight and Government Reform of his intent not…
-
Independent group says new Glaxo asthma drug far too expensive
An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines found the price of GlaxoSmithKline’s new drug for severe asthma should be as much as 76 percent lower to justify its value, according to the group’s latest draft report. The Boston-based Institute for Clinical and Economic Review (ICER) said its analysis indicated…